The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2023 | Utilizing cytokine profiles at baseline to predict cytopenia after treatment with ide-cel
Razan Mohty, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of a study investigating the impact of cytokines at baseline on the occurrence of cytopenia at six months following treatment with idecabtagene vicleucel (ide-cel) in patients with multiple myeloma. The study found that the whilst the presence of pro-inflammatory cytokines was associated with cytopenia after ide-cel infusion, angiopoietin-1 expression correlated with hematopoietic recovery. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
